Back to Search Start Over

The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes.

Authors :
Pavón MA
Arroyo-Solera I
León X
Téllez-Gabriel M
Virós D
Gallardo A
Céspedes MV
Casanova I
Lopez-Pousa A
Barnadas A
Quer M
Mangues R
Source :
Head & neck [Head Neck] 2019 Jun; Vol. 41 (6), pp. 1830-1845. Date of Electronic Publication: 2019 Jan 16.
Publication Year :
2019

Abstract

Background: We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial-like (EL) or mesenchymal-like (ML) phenotypes.<br />Materials and Methods: We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.<br />Results: EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93-gene expression signature between ML and EL cells was used to build a three-gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA-seq data of the TCGA-HNSC project. Its prognostic value was confirmed in two independent cohorts.<br />Conclusion: EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.<br /> (© 2019 Wiley Periodicals, Inc.)

Details

Language :
English
ISSN :
1097-0347
Volume :
41
Issue :
6
Database :
MEDLINE
Journal :
Head & neck
Publication Type :
Academic Journal
Accession number :
30652380
Full Text :
https://doi.org/10.1002/hed.25623